Management of Menopausal Symptoms
Menopause hormone therapy (MHT) has been proven to be the most effective treatment for menopausal symptoms and is an acceptable option among many women up to 59 years of age. However, consideration of other treatment options may be necessary for women who are not able or do not want to take MHT. Because of the potential risks of long-term MHT use, it is equally important to ensure that women between the ages of 60-65 years stop using MHT unless deemed appropriate. Further, breast cancer risk increases with age. Medications to reduce risk for primary breast cancer are recommended for women at increased risk, but use is low. Issues at both sides of this age spectrum (under and over 60 years) are important and require different management strategies. It is important to offer appropriate and individualized treatment options.
This project was designed to evaluate a patient-centered, shared decision making intervention in 9 primary care practices that use an Electronic Health Record (EHR) and have a wireless Internet connection. Tablet computer technology was integrated into practice workflow and results of health risk appraisal tools (menopause rating scale and breast cancer risk assessment tool) were able to be incorporated into the EHR for shared decision making at the point of care. The target audiences for this intervention are primary care providers and staff caring for women ages 45-65, and any women presenting for an appointment to her provider 45-65 years of age.
The primary aims of this study were to:
- Evaluate the impact of improved information collection and documentation of diagnosis of menopause or postmenopausal symptoms
- Assess patient and provider satisfaction with the shared decision making process
Secondary aims addressed medication use and communication between patients and providers.
This active intervention was from January 2014 through August 2015.
Data analysis is currently in progress.
Key Findings and Publications
Please check back at a later date for research results and key findings.
For additional information about this study, please contact:
Laura Borgelt, PharmD, FCCP, BCPS, NCMP
Professor, Departments of Clinical Pharmacy and Family Medicine
Associate Dean of Administration and Operations
University of Colorado Anschutz Medical Campus
This study is funded by grants from Pfizer Independent Grants for Learning & Change